Skip to main content

Table 3 Correlation between target gene protein levels and clinicopathological parameters of 99 BC cases

From: Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivotumor growth

Variable

EIF4A2

ANKRD46

 

Low (n = 21)

High (n = 78)

P*

Low (n = 47)

High (n = 52)

P*

Age (years)

      

   < 48

8

39

0.332

23

24

0.782

   ≥ 48

13

39

 

24

28

 

Pathologic grade

      

   I

2

20

0.115

14

10

0.221

   II, III

19

58

 

33

42

 

Clinical stage**

      

   I, II

15

61

0.514

41

37

0.051

   III

6

17

 

6

15

 

Lymph node status

      

   Metastasis

14

43

0.342

23

34

0.098

   No Metastasis

7

35

 

24

18

 

ER status

      

Negative

12

36

0.371

18

32

0.021

Positive

9

42

 

29

20

 

PR status

      

Negative

11

28

0.170

11

29

0.001

Positive

10

50

 

36

23

 

CerbB2 status

      

0,1+

17

41

0.019

29

18

0.832

2+,3+

4

37

 

31

21

 
  1. *Two-sided Pearson Chi-Square Test; ** there were no stage IV patients because all the cases selected were surgical patients without neoadjuvant therapy to avoid the effect of the preoperative radiotherapy and/or chemotherapy on miRNAs; EIF4A2, eukaryotic translation initiation factor 4A2 protein; ANKRD46, ankyrin repeat domain 46 protein; ER, estrogen receptor; PR, progesterone receptor; CerbB2, v-erb-b2 erythroblastic leukaemia viral oncogene homolog 2 receptors.